Scientific article on Episealer® Talus surgical technique published in Foot & Ankle Clinics
Episurf Medical (Nasdaq: EPIS B) today announces that an article on the surgical technique for Episurf Medical’s implant system for treatment for osteochondral defects in the ankle joint, Episealer® Talus, has been published in the scientific journal Foot & Ankle Clinics. The publication, with the title “Personalized Resurfacing for Osteochondral Lesions of the Talus”, by F. G. Usuelli, MD, B. Efrima, MD and Prof. N. van Dijk, covers areas such as the etiology of typical ankle lesions and alternative treatment methodologies, in addition to providing a detailed review of the surgical technique for Episealer® Talus.
The authors state that osteochondral lesions of the talus (OLTs) are the most common cause of chronic deep ankle pain and that treating symptomatic OLTs can be challenging. The authors further conclude that they believe that the Episealer® Talus technique is proven effective, that they have had positive experiences from using the technique, and that the treatment alternative serves as a viable treatment option for OLTs and can serve as a bridge between biologics and conventional joint arthroplasty.
“This is a welcome addition to the library of scientific publications on the Episealer® technology. Over the years, surgeons have given us very positive feedback on the user-friendliness of our technology, and they have testified to the precision and accuracy of the surgical pre-planning, surgical drill guides, and implants. We are pleased to see this scientific paper being published, and that the lack of compromises on implant location, size, and shape is highlighted as true benefits of our patient-specific technology – which we fully agree with,” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 10:50 CEST on 14 September 2023.
Tags: